TL;DR
This study reveals that nearly 11% of patients undergoing ablation for scar-related ventricular tachycardia (VT) have cardiac thrombi, a significant risk factor for stroke. By systematically screening with cardiac CT, clinicians can identify these thrombi, tailor ablation strategies, and drastically reduce embolic complications to a mere 0.3%.
What Problem Does This Paper Address?
Ventricular tachycardia (VT) ablation is a crucial treatment for patients with structural heart disease (SHD) experiencing life-threatening arrhythmias. However, a significant risk associated with this procedure is embolic events, particularly stroke, which can occur in up to 2.7% of cases. While current guidelines suggest imaging to rule out intra-cardiac thrombi in SHD patients, there's been a lack of robust data guiding optimal screening strategies and management for these patients. This leaves a gap in understanding the true prevalence of thrombi and how best to mitigate the associated embolic risks during VT ablation.
Methods
The researchers conducted a retrospective analysis of 618 patients referred for VT ablation between January 2015 and December 2019. A key aspect of their methodology was the systematic pre-procedure cardiac computed tomography (cCT) scan performed on 401 patients undergoing de novo, scar-related VT ablation. This imaging protocol, performed within 7 days of ablation, aimed to identify the arrhythmogenic substrate and, crucially, exclude intra-cardiac thrombi. The cCT scans were independently reviewed by two radiologists. They also collected detailed demographic, clinical, procedural, and outcome data from electronic medical records. Statistical analysis involved univariable and multivariable logistic regression to identify predictors of thrombus formation.
Datasets
The study utilized data from 401 patients who underwent pre-ablation cCT scans. This dataset represents patients referred for de novo, scar-related VT ablation at a single center. No new benchmarks were introduced; rather, existing patient data was analyzed.
Key Insights and Ideas
- Thrombus is Common: The most striking finding is the high prevalence of intra-cardiac thrombi (11%) in patients undergoing VT ablation for scar-related disease. This suggests that current screening practices might be insufficient.
- Risk Factors Identified: The study pinpoints key predictors for thrombus formation, including left ventricular (LV) aneurysm, reduced LV ejection fraction (LVEF < 40%), altered right ventricular ejection fraction (RVEF), and electrical storm. This provides actionable targets for risk stratification.
- Tailored Ablation Works: When thrombi are identified, personalized ablation strategies (e.g., epicardial approach for LV thrombi, retrograde-aortic access for LAA thrombi) and avoiding inducibility testing can be employed to significantly reduce embolic risk.
- cCT is Effective: Cardiac CT proved to be a valuable tool for identifying thrombi, with a very low rate of embolic complications (0.3%) observed in the entire cohort, highlighting the benefit of systematic screening.
- LAA Thrombi and AF: Left atrial appendage (LAA) thrombi were exclusively found in patients with atrial fibrillation (AF), underscoring the importance of screening this subgroup, even if they are already on anticoagulation.
Key Results
- Prevalence: 11% of patients (45 out of 401) had intra-cardiac thrombi detected by cCT.
- Thrombus Locations: The majority of thrombi were found in the LV (29), followed by LAA (8), right ventricle (RV) (8), and right atrium (RA) (4).
- Predictors: Multivariable analysis identified LV aneurysm (OR: 6.6), LVEF < 40% (OR: 3.3), electrical storm (OR: 2.9), and RV systolic dysfunction (OR: 2.3) as independent predictors of cardiac thrombus.
- Embolic Complications: The overall rate of ablation-related embolic events was very low at 0.3% (1 patient). Notably, none of the seven patients with thrombus who underwent ablation experienced an embolic event.
- LAA Thrombus in AF: 5.6% of patients with AF had LAA thrombi, even while on anticoagulation.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-Center Study: The findings are from a single, highly experienced center, which may limit generalizability.
- Retrospective Design: The retrospective nature of the study means it cannot establish causality definitively.
- Low Female Representation: Women constituted only 9% of the study population, which is attributed to the underlying IHD substrate in scar-related VT. This limits the ability to draw conclusions specific to female patients.
- cCT vs. Other Modalities: While cCT was used in the majority, it wasn't systematically compared with other imaging modalities like echocardiography (though some comparisons were made, showing cCT's superiority for LV thrombus detection).
Future work could involve prospective, multi-center studies to validate these findings and explore the long-term outcomes of patients with identified thrombi. Further research into optimizing anticoagulation strategies for patients with LAA thrombi undergoing VT ablation is also warranted. The study also suggests that cCT's utility extends beyond thrombus detection, aiding in scar identification and critical structure localization, which could be further explored.
Summary updated